U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H6ClF2N3O
Molecular Weight 269.635
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ICA-069673

SMILES

FC1=C(F)C=C(C=C1)C(=O)NC2=CN=C(Cl)N=C2

InChI

InChIKey=IIBSHMFXVWTQSJ-UHFFFAOYSA-N
InChI=1S/C11H6ClF2N3O/c12-11-15-4-7(5-16-11)17-10(18)6-1-2-8(13)9(14)3-6/h1-5H,(H,17,18)

HIDE SMILES / InChI

Molecular Formula C11H6ClF2N3O
Molecular Weight 269.635
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

The novel compound ICA-069673 was developed by Icagen, Inc. in a screening program to identify subtype-selective KV7 channel activators. It was found, that this compound is a selective KV7.2/KV7.3 (KCNQ2/3) channel opener, which possesses 20-fold selectivity for KV7.2/KV7.3 over KV7.3/KV7.5, with no measurable activity over a panel of cardiac ion channels. ICA-06967 was orally active in animal models and was used for epilepsy.

Originator

Curator's Comment: The novel compound ICA-069673 was developed by Icagen, Inc. (Durham, NC) in a screening program to identify subtype-selective KV7 channel activators

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.38 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed

Sample Use Guides

in rats: maximal electroshock (MES) and the PTZ anticonvulsant assays: MES ED50 = 1.5 mg/kg, PTZ ED50 = 2.2 mg/kg
Route of Administration: Oral
It was measured the effects of ICA-069673 on global intracellular Ca2+ levels in detrusor smooth muscle (DSM) single cells. For the control, the average emitted intensity (F340/F380) prior to ICA-069673 application was 0.470 ± 0.006 (n = 11, N = 5). At 10 μM ICA-069673, there was a significant decrease in the F340/F380 ratio to 0.450 ± 0.006 (n = 11, N = 5; P < 0.001). To elucidate the mechanism by which ICA-069673 regulates global intracellular Ca2+ concentrations, it was studied the effects of ICA-069673 (10 µM) in the presence or absence of the L-type CaV channel blocker nifedipine (1 µM). In the presence of 1 µM nifedipine, ICA-069673 (10 µM) had no significant effect on global intracellular Ca2+ levels, with the average F340/F380 ratio being 0.470 ± 0.008 compared with the control value of 0.480 ± 0.005 (n = 11, N = 5; P > 0.05). These results demonstrate that in DSM cells, ICA-069673 decreases global intracellular Ca2+ concentrations by an indirect mechanism involving inhibition of Ca2+influx through L-type CaV channels, probably as a result of membrane hyperpolarization.
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:18:26 GMT 2023
Edited
by admin
on Sat Dec 16 11:18:26 GMT 2023
Record UNII
NCO5DC74G8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ICA-069673
Common Name English
BENZAMIDE, N-(2-CHLORO-5-PYRIMIDINYL)-3,4-DIFLUORO-
Systematic Name English
ICA-69673
Code English
N-(2-CHLORO-5-PYRIMIDINYL)-3,4-DIFLUOROBENZAMIDE
Systematic Name English
N-(2-CHLOROPYRIMIDIN-5-YL)-3,4-DIFLUORO-BENZAMIDE
Systematic Name English
Code System Code Type Description
CAS
582323-16-8
Created by admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
PRIMARY
PUBCHEM
10149311
Created by admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
PRIMARY
WIKIPEDIA
KvLQT2
Created by admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
PRIMARY ICA-069673: channel opener at KCNQ2/Q3, 20-fold selective over KCNQ3/Q5, no measurable activity against a panel of cardiac ion channels (hERG, Nav1.5, L type channels, and KCNQ1) and no activity on GABAA gated channels at 10 .MU.M. A range of related benzamides exhibited activity, of which compound number 40 is shown here. ML252: channel inhibitor, IC50 = 70nM.
MANUFACTURER PRODUCT INFORMATION
ICA-069673
Created by admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
PRIMARY ICA 069673 is a potassium channel opener with selective action for KCNQ2 and KCNQ3 (EC50=0.69 .MU.M). No measurable activity was displayed over a variety of cardiac ion channels. IC50: Voltage-gated potassium channel, KQT; KCNQ2(Kv7.2)/KCNQ3(Kv7.3): EC5050 = 0.69 undefinedM (human); HERG: IC50 >30 undefinedM (human); Na+ CP type V.ALPHA.: IC50 >30 undefinedM (human) - pK Values: pKa: 9.47 (Predicted)
FDA UNII
NCO5DC74G8
Created by admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
Biological Activity: Selective KV7.2/KV7.3 (KCNQ2/3) channel opener (EC50 = 0.69 .MU.M). Exhibits 20-fold selectivity for KV7.2/KV7.3 over KV7.3/KV7.5, with no measurable activity over a panel of cardiac ion channels. Hyperpolarizes resting membrane potential and inhibits spontaneous action potentials in guinea pig detrusor muscle (DSM) isolated cells. Orally active in animal models of epilepsy.
ACTIVE MOIETY
ICA 069673 is a potassium channel opener with selective action for KCNQ2 and KCNQ3 (EC50=0.69 .MU.M). No measurable activity was displayed over a variety of cardiac ion channels.